First Time Loading...

Yield10 Bioscience Inc
NASDAQ:YTEN

Watchlist Manager
Yield10 Bioscience Inc Logo
Yield10 Bioscience Inc
NASDAQ:YTEN
Watchlist
Price: 0.3751 USD 9.61%
Updated: Mar 28, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Yield10 Bioscience Inc

Revenue
150k USD
Operating Expenses
-14.5m USD
Operating Income
-14.4m USD
Other Expenses
-120k USD
Net Income
-14.5m USD

Margins Comparison
Yield10 Bioscience Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Yield10 Bioscience Inc
NASDAQ:YTEN
4.5m USD
-9 580%
-9 660%
US
Abbvie Inc
NYSE:ABBV
318.5B USD
30%
9%
US
Amgen Inc
NASDAQ:AMGN
153.3B USD
29%
24%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.5B USD
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.7B USD
32%
30%
US
Gilead Sciences Inc
NASDAQ:GILD
91B USD
30%
21%
AU
CSL Ltd
ASX:CSL
138.3B AUD
26%
17%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Moderna Inc
NASDAQ:MRNA
42.2B USD
-62%
-69%
US
Biogen Inc
NASDAQ:BIIB
31.3B USD
21%
12%
KR
Celltrion Inc
KRX:068270
40.2T KRW
32%
26%
Country US
Market Cap 4.5m USD
Operating Margin
-9 580%
Net Margin
-9 660%
Country US
Market Cap 318.5B USD
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 153.3B USD
Operating Margin
29%
Net Margin
24%
Country US
Market Cap 107.5B USD
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 105.7B USD
Operating Margin
32%
Net Margin
30%
Country US
Market Cap 91B USD
Operating Margin
30%
Net Margin
21%
Country AU
Market Cap 138.3B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 42.2B USD
Operating Margin
-62%
Net Margin
-69%
Country US
Market Cap 31.3B USD
Operating Margin
21%
Net Margin
12%
Country KR
Market Cap 40.2T KRW
Operating Margin
32%
Net Margin
26%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Yield10 Bioscience Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Yield10 Bioscience Inc
NASDAQ:YTEN
4.5m USD
-381%
-168%
-250%
-439%
US
Abbvie Inc
NYSE:ABBV
318.5B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
153.3B USD
136%
8%
13%
11%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.5B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.7B USD
16%
13%
15%
32%
US
Gilead Sciences Inc
NASDAQ:GILD
91B USD
26%
9%
16%
12%
AU
CSL Ltd
ASX:CSL
138.3B AUD
15%
7%
11%
9%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Moderna Inc
NASDAQ:MRNA
42.2B USD
-29%
-21%
-23%
-41%
US
Biogen Inc
NASDAQ:BIIB
31.3B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
40.2T KRW
14%
10%
16%
11%
Country US
Market Cap 4.5m USD
ROE
-381%
ROA
-168%
ROCE
-250%
ROIC
-439%
Country US
Market Cap 318.5B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 153.3B USD
ROE
136%
ROA
8%
ROCE
13%
ROIC
11%
Country US
Market Cap 107.5B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 105.7B USD
ROE
16%
ROA
13%
ROCE
15%
ROIC
32%
Country US
Market Cap 91B USD
ROE
26%
ROA
9%
ROCE
16%
ROIC
12%
Country AU
Market Cap 138.3B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 42.2B USD
ROE
-29%
ROA
-21%
ROCE
-23%
ROIC
-41%
Country US
Market Cap 31.3B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 40.2T KRW
ROE
14%
ROA
10%
ROCE
16%
ROIC
11%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More